ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
ProPhase Labs, Inc. (PRPH) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $53.76 per share as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2026-08-19
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $53.76.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $53.72.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $55.54.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $5.66.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $53.76 10-Q · filed 2026-08-19 |
| 2026-03-31 | $53.72 10-Q/A · filed 2026-07-09 |
| 2025-12-31 | $55.54 10-K · filed 2026-06-01 |
| 2025-09-30 | $5.66 10-Q · filed 2025-11-19 |
| 2025-06-30 | $6.14 10-Q · filed 2025-08-13 |
| 2025-03-31 | $6.03 10-Q · filed 2025-05-20 |
| 2024-12-31 | $6.55 10-K · filed 2025-04-01 |
| 2024-09-30 | $6.55 10-Q · filed 2024-11-13 |
| 2024-06-30 | $6.53 10-Q · filed 2024-08-14 |
| 2024-03-31 | $6.43 10-Q · filed 2024-05-10 |
| 2023-12-31 | $6.69 10-K · filed 2024-03-29 |
| 2019-06-30 | $1.88 10-Q · filed 2019-08-12 |
| 2019-03-31 | $1.88 10-Q · filed 2019-05-14 |
| 2018-12-31 | $2.00 10-K · filed 2019-03-26 |
| 2018-06-30 | $1.88 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |